title: CT contrast predicts pancreatic cancer treatment response to verteporfin-based photodynamic therapy.
abstract: The goal of this study was to determine dominant factors affecting treatment response in pancreatic cancer photodynamic therapy (PDT), based on clinically available information in the VERTPAC-01 trial. This trial investigated the safety and efficacy of verteporfin PDT in 15 patients with locally advanced pancreatic adenocarcinoma. CT scans before and after contrast enhancement from the 15 patients in the VERTPAC-01 trial were used to determine venous-phase blood contrast enhancement and this was correlated with necrotic volume determined from post-treatment CT scans, along with estimation of optical absorption in the pancreas for use in light modeling of the PDT treatment. Energy threshold contours yielded estimates for necrotic volume based on this light modeling. Both contrast-derived venous blood content and necrotic volume from light modeling yielded strong correlations with observed necrotic volume (R² = 0.85 and 0.91, respectively). These correlations were much stronger than those obtained by correlating energy delivered versus necrotic volume in the VERTPAC-01 study and in retrospective analysis from a prior clinical study. This demonstrates that contrast CT can provide key surrogate dosimetry information to assess treatment response. It also implies that light attenuation is likely the dominant factor in the VERTPAC treatment response, as opposed to other factors such as drug distribution. This study is the first to show that contrast CT provides needed surrogate dosimetry information to predict treatment response in a manner which uses standard-of-care clinical images, rather than invasive dosimetry methods.
authors.affiliation: Thayer School of Engineering, Dartmouth College, Hanover, NH-03755, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Jermyn
authors.forename: Scott C
authors.initials: SC
authors.lastname: Davis
authors.forename: Hamid
authors.initials: H
authors.lastname: Dehghani
authors.forename: Matthew T
authors.initials: MT
authors.lastname: Huggett
authors.forename: Tayyaba
authors.initials: T
authors.lastname: Hasan
authors.forename: Stephen P
authors.initials: SP
authors.lastname: Pereira
authors.forename: Stephen G
authors.initials: SG
authors.lastname: Bown
authors.forename: Brian W
authors.initials: BW
authors.lastname: Pogue
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000188:drug therapy; D006801:Humans; D058958:Organs at Risk / Q000528:radiation effects; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D010778:Photochemotherapy / Q000009:adverse effects; D011166:Porphyrins / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D000077362:Verteporfin
chemical_list: D011166:Porphyrins; D000077362:Verteporfin